董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kenneth Carter | 男 | Executive Chairman | 60 | 84.04万美元 | 未持股 | 2020-03-15 |
| Sanford D. Smith | 男 | Director | 73 | 10.00万美元 | 未持股 | 2020-03-15 |
| Binxian Wei | 男 | Director | 50 | 8.41万美元 | 未持股 | 2020-03-15 |
| David J. Mazzo | 男 | Director | 63 | 5.48万美元 | 未持股 | 2020-03-15 |
| Cristina Csimma | 女 | Director | 61 | 10.00万美元 | 未持股 | 2020-03-15 |
| Mary Ann Gray | 女 | Director | 67 | 4.64万美元 | 未持股 | 2020-03-15 |
| Scott V. Ogilvie | 男 | Director | 68 | 10.00万美元 | 未持股 | 2020-03-15 |
高管介绍
暂无数据
董事简历
中英对照 | 中文 | 英文- Kenneth Carter
-
暂无中文简介
Kenneth Carter has served as our executive chairman since January 2019. Dr. Carter has over 20 years of experience working in positions of substantial responsibility in the development and operations of early-stage biotechnology companies. Since 2010 when he co-founded the company, Dr. Carter has served as chairman of the board of directors of Noble Life Sciences, a private biotechnology company in Maryland. From 2011 through 2017 Dr. Carter served as president and chief executive officer of Neximmune, Inc., a private biopharmaceutical company in Maryland. He continues to serve as senior advisor of NexImmune. Prior to that, from 1999 through 2009 Dr. Carter served as president and chief executive officer of Avalon Pharmaceuticals, Inc. NASDAQ: AVRX until the company merged with Clinical Data, Inc. Dr. Carter also currently serves on the following boards of directors (i) since 2016 Antidote Therapeutics, Inc., a private biopharmaceutical company in Maryland, (ii) since 2011 BetaCat Pharmaceuticals, a private pharmaceutical company in Texas, and Maryland BioHealth Innovation, a biotechnology intermediary company in Maryland, and (iii) since 2007 Maryland Health Care Product Development Corporation, a biotechnology investment firm in Maryland. Dr. Carter additionally serves as a lecturer and Adjunct Faculty member of Johns Hopkins University in Maryland. Dr. Carter holds a BS in Biology and Chemistry from Abilene Christian University, a Ph.D. in Human Genetics and Cell Biology from the University of Texas Medical Branch, and a Postdoctoral degree in Cell and Molecular Biology from University of Massachusetts Medical School. -
暂无中文简介
- Kenneth Carter has served as our executive chairman since January 2019. Dr. Carter has over 20 years of experience working in positions of substantial responsibility in the development and operations of early-stage biotechnology companies. Since 2010 when he co-founded the company, Dr. Carter has served as chairman of the board of directors of Noble Life Sciences, a private biotechnology company in Maryland. From 2011 through 2017 Dr. Carter served as president and chief executive officer of Neximmune, Inc., a private biopharmaceutical company in Maryland. He continues to serve as senior advisor of NexImmune. Prior to that, from 1999 through 2009 Dr. Carter served as president and chief executive officer of Avalon Pharmaceuticals, Inc. NASDAQ: AVRX until the company merged with Clinical Data, Inc. Dr. Carter also currently serves on the following boards of directors (i) since 2016 Antidote Therapeutics, Inc., a private biopharmaceutical company in Maryland, (ii) since 2011 BetaCat Pharmaceuticals, a private pharmaceutical company in Texas, and Maryland BioHealth Innovation, a biotechnology intermediary company in Maryland, and (iii) since 2007 Maryland Health Care Product Development Corporation, a biotechnology investment firm in Maryland. Dr. Carter additionally serves as a lecturer and Adjunct Faculty member of Johns Hopkins University in Maryland. Dr. Carter holds a BS in Biology and Chemistry from Abilene Christian University, a Ph.D. in Human Genetics and Cell Biology from the University of Texas Medical Branch, and a Postdoctoral degree in Cell and Molecular Biology from University of Massachusetts Medical School.
- Sanford D. Smith
-
暂无中文简介
Sanford D. Smith, served on our board of directors from March 2014 until March 26 2020 the date that he resigned from our board. Since December 2011 Mr. Smith has served as Founder and Chairman of Global Biolink Partners. From 1996 until 2011 Mr. Smith served in various senior and executive management positions at Genzyme Corporation Formerly NASDAQ: GENZ, including Executive Vice President and President, International Group with responsibility for the commercial activities for Genzyme’s products outside of the U.S. Prior to joining Genzyme, Mr. Smith served from 1986 to 1996 as President and Chief Executive Officer and a Director of Repligen Corporation, a formerly publicly traded biotechnology company. Mr. Smith previously held a number of positions with Bristol-Myers Squibb Company (NYSE: BMY) from 1977 to 1986 including Vice President of Business Development and Strategic Planning for the Pharmaceutical Group. Mr. Smith currently serves as a director of Cytokynetics, Inc. (NASDAQ: CYTK), Apricus Biosciences, Inc. (NASDAQ: APRI) and as chairman of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) and. Mr. Smith serves as a member of the President’s Advisory Board of Brigham and Women’s Hospital in Boston, member of the Advisory Board of Tullis Health Investors in Greenwich, and an advisor to BioNEST Partners in New York and Paris. Mr. Smith also is the founder of Smith Scholars, a medical residency program for physicians from resource-poor nations. -
暂无中文简介
- Sanford D. Smith, served on our board of directors from March 2014 until March 26 2020 the date that he resigned from our board. Since December 2011 Mr. Smith has served as Founder and Chairman of Global Biolink Partners. From 1996 until 2011 Mr. Smith served in various senior and executive management positions at Genzyme Corporation Formerly NASDAQ: GENZ, including Executive Vice President and President, International Group with responsibility for the commercial activities for Genzyme’s products outside of the U.S. Prior to joining Genzyme, Mr. Smith served from 1986 to 1996 as President and Chief Executive Officer and a Director of Repligen Corporation, a formerly publicly traded biotechnology company. Mr. Smith previously held a number of positions with Bristol-Myers Squibb Company (NYSE: BMY) from 1977 to 1986 including Vice President of Business Development and Strategic Planning for the Pharmaceutical Group. Mr. Smith currently serves as a director of Cytokynetics, Inc. (NASDAQ: CYTK), Apricus Biosciences, Inc. (NASDAQ: APRI) and as chairman of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) and. Mr. Smith serves as a member of the President’s Advisory Board of Brigham and Women’s Hospital in Boston, member of the Advisory Board of Tullis Health Investors in Greenwich, and an advisor to BioNEST Partners in New York and Paris. Mr. Smith also is the founder of Smith Scholars, a medical residency program for physicians from resource-poor nations.
- Binxian Wei
-
暂无中文简介
Binxian Wei, has served on our board of directors since February 2019. He has been the V.P. of Darsheng Trade & Tech. Development Co, Ltd. a subsidiary to Tianjin Tiayo Pharmaceutical Co., Ltd. since 2015. He is responsible for API and finished dosage marketing for Chinese pharmaceutical companies. From 2008 through 2010 he worked as a business development manager for Sakai Trading. He holds a Master’s degree in Mathematical & Computer Sciences from Colorado School of Mines, a Master’s Degree and Bachelor’s Degree in Chemical Engineering from Tianjin University in China. Bin-Xian Wei was appointed as the director representative of the Series A 4.5 Convertible Preferred Stock by Tianjin Pharmaceuticals Group International Holdings Co., LTD, the sole holder of the outstanding Series A 4.5 Convertible Preferred Stock. -
暂无中文简介
- Binxian Wei, has served on our board of directors since February 2019. He has been the V.P. of Darsheng Trade & Tech. Development Co, Ltd. a subsidiary to Tianjin Tiayo Pharmaceutical Co., Ltd. since 2015. He is responsible for API and finished dosage marketing for Chinese pharmaceutical companies. From 2008 through 2010 he worked as a business development manager for Sakai Trading. He holds a Master’s degree in Mathematical & Computer Sciences from Colorado School of Mines, a Master’s Degree and Bachelor’s Degree in Chemical Engineering from Tianjin University in China. Bin-Xian Wei was appointed as the director representative of the Series A 4.5 Convertible Preferred Stock by Tianjin Pharmaceuticals Group International Holdings Co., LTD, the sole holder of the outstanding Series A 4.5 Convertible Preferred Stock.
- David J. Mazzo
-
David J. Mazzo, 从2008年8月起担任公司CEO和董事会成员。他在制药行业有将近30年经验。2007年3月-2008年4月，他担任terna Zentaris--一家上市国际生物制药公司的总裁、CEO兼董事。2003-2007年，他担任美国Chugai制药公司总裁、CEO兼董事，Chugai是一家生物制药公司，是日本Chugai制药公司的美国子公司。他也担任过研发部高级管理和行政职位，曾是艾塞克斯奇美欧洲子公司先灵葆雅公司董事，先灵葆雅是一家上市制药公司，后被默克公司收购；Hoechst Marion Roussel公司是Hoechst公司的美国子公司，后被赛诺菲制药集团收购，赛诺菲是一家跨国制药公司； Rhone-Poulenc Rorer公司是Rhone-Poulene SA子公司，后者是一家法国制药公司，后来被Hoechst AG公司收购。他目前在pSivida公司--上市生物科技公司的董事会任职，担任非执行董事长；也在Avanir 制药公司--上市生物科技公司的董事会任职。他拥有荣誉项目跨学科人文学士学位和维纳诺瓦大学化学学士学位。另外，他还拥有艾摩斯特马萨诸塞大学化学硕士和分析化学博士学位。他同时也是瑞士洛桑巴黎理工大学的一名研究人员。
David J. Mazzo has served on our board of directors since June 2019. Dr. Mazzo currently serves as President and Chief Executive Officer and a Director of Caladrius Biosciences NASDAQ: CLBS, a late-stage therapeutics development biopharmaceutical company developing autologous cell therapies for select cardiovascular and autoimmune diseases. Dr. Mazzo also serves on the Board of Directors of EyePoint Pharmaceuticals (formerly known as pSivida Corp) (NASDAQ: EYPT), a biopharmaceutical company with a focus on products for the diseases of the eye. Previously, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc., (NASDAQ: RGDO) a pharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008 Dr. Mazzo was President, Chief Executive Officer and a Director of terna Zentaris, Inc., (NASDAQ: AEZS), an international biopharmaceutical company. From 2003 until 2007 Dr. Mazzo served as President, Chief Executive Officer and a director of Chugai Pharma USA, LLC, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan and a member of the Roche Group (Switzerland). Prior to joining Chugai, Dr. Mazzo held executive positions at several large international pharmaceutical companies, including: Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc. where he was also a Director of the Essex Chimie European subsidiary; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, which was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, which was subsequently acquired by Hoechst AG. From October 2005 through January 2015 he also served on the board of directors of Avanir Pharmaceuticals, a biopharmaceutical company which was sold to Otsuka Holdings in 2015. Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in analytical chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland. - David J. Mazzo, 从2008年8月起担任公司CEO和董事会成员。他在制药行业有将近30年经验。2007年3月-2008年4月，他担任terna Zentaris--一家上市国际生物制药公司的总裁、CEO兼董事。2003-2007年，他担任美国Chugai制药公司总裁、CEO兼董事，Chugai是一家生物制药公司，是日本Chugai制药公司的美国子公司。他也担任过研发部高级管理和行政职位，曾是艾塞克斯奇美欧洲子公司先灵葆雅公司董事，先灵葆雅是一家上市制药公司，后被默克公司收购；Hoechst Marion Roussel公司是Hoechst公司的美国子公司，后被赛诺菲制药集团收购，赛诺菲是一家跨国制药公司； Rhone-Poulenc Rorer公司是Rhone-Poulene SA子公司，后者是一家法国制药公司，后来被Hoechst AG公司收购。他目前在pSivida公司--上市生物科技公司的董事会任职，担任非执行董事长；也在Avanir 制药公司--上市生物科技公司的董事会任职。他拥有荣誉项目跨学科人文学士学位和维纳诺瓦大学化学学士学位。另外，他还拥有艾摩斯特马萨诸塞大学化学硕士和分析化学博士学位。他同时也是瑞士洛桑巴黎理工大学的一名研究人员。
- David J. Mazzo has served on our board of directors since June 2019. Dr. Mazzo currently serves as President and Chief Executive Officer and a Director of Caladrius Biosciences NASDAQ: CLBS, a late-stage therapeutics development biopharmaceutical company developing autologous cell therapies for select cardiovascular and autoimmune diseases. Dr. Mazzo also serves on the Board of Directors of EyePoint Pharmaceuticals (formerly known as pSivida Corp) (NASDAQ: EYPT), a biopharmaceutical company with a focus on products for the diseases of the eye. Previously, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc., (NASDAQ: RGDO) a pharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008 Dr. Mazzo was President, Chief Executive Officer and a Director of terna Zentaris, Inc., (NASDAQ: AEZS), an international biopharmaceutical company. From 2003 until 2007 Dr. Mazzo served as President, Chief Executive Officer and a director of Chugai Pharma USA, LLC, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan and a member of the Roche Group (Switzerland). Prior to joining Chugai, Dr. Mazzo held executive positions at several large international pharmaceutical companies, including: Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc. where he was also a Director of the Essex Chimie European subsidiary; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, which was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, which was subsequently acquired by Hoechst AG. From October 2005 through January 2015 he also served on the board of directors of Avanir Pharmaceuticals, a biopharmaceutical company which was sold to Otsuka Holdings in 2015. Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in analytical chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.
- Cristina Csimma
-
Cristina Csimma，女，药学博士，自2010年9月起担任本公司董事。自2012年11月起，担任Cydan, Inc.负责罕见疾病治疗的首席执行官。之前在生物制药和投资行业以及政府和患者组织担任战略咨询的角色。2009年1月至2011年5月担任Virdante制药公司负责药物开发的副总裁。从2006年到2008年担任Clarus Ventures有限责任公司（生命科学风险投资）的主管。2001至2006年担任惠氏研究（制药）的 资深总监/董事，负责实验医学和转化研究。2000至2001年担任惠氏研究（制药）负责临床研究和开发的主任。此前担任多个职位，包括1988年至2000年担任遗传学研究所临床研究的副主任，自1983年至1988年于Dana-Farber癌症研究所担任临床药师。持有美国马萨诸塞药学院及联合健康科学学院的药学学士学位和博士学位，并从东北大学获得卫生专业硕士学位。
Cristina Csimma currently serves as a board director and chair of the Nominating and Corporate Governance Committee of Seneca Biopharma, Inc. previously, Neuralstem Inc. (CUR), having been elected to its board of directors in September 2017. She also serves as the chair of the board of directors of Caraway Therapeutics since April of 2019 (executive chair in 2019), and as a board director of T1D Exchange (non-profit-Type 1 Diabetes), a position she has held since December 2018. She also serves on advisory boards including the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee since 2006; the Harvard and Brigham and Women's Hospital MRCT Center External Advisory Board since 2015 and the TREAT-NMD Advisory Committee for Therapeutics (TACT) since 2009. Dr. Csimma previously served as a Director on the boards of Juniper Pharma (from 2010 until its acquisition by Catalent in 2018), Vtesse Pharma (from 2014 until its acquisition by Sucampo in 2017), was the executive chair and a senior advisor of Exonics Therapeutics (from 2016 to 2017), and was President, founding CEO and board director of Cydan Inc. from 2012 to 2014. She also served on the NIH Blueprint Neurotherapeutics Network External Oversight Committee from 2014 to 2018 the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network from 2013 until 2017 was Vice President of Drug Development at Virdante Pharmaceuticals Inc. from 2009 to 2011 Principal at Clarus Ventures LLC (now Blackstone Life Science) and held roles of increasing responsibility in Clinical Development and Translational Research at Wyeth (now Pfizer), Genetics Institute and Dana Farber Cancer Institute. Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, as well as a Master of Health Professions from Northeastern University. - Cristina Csimma，女，药学博士，自2010年9月起担任本公司董事。自2012年11月起，担任Cydan, Inc.负责罕见疾病治疗的首席执行官。之前在生物制药和投资行业以及政府和患者组织担任战略咨询的角色。2009年1月至2011年5月担任Virdante制药公司负责药物开发的副总裁。从2006年到2008年担任Clarus Ventures有限责任公司（生命科学风险投资）的主管。2001至2006年担任惠氏研究（制药）的 资深总监/董事，负责实验医学和转化研究。2000至2001年担任惠氏研究（制药）负责临床研究和开发的主任。此前担任多个职位，包括1988年至2000年担任遗传学研究所临床研究的副主任，自1983年至1988年于Dana-Farber癌症研究所担任临床药师。持有美国马萨诸塞药学院及联合健康科学学院的药学学士学位和博士学位，并从东北大学获得卫生专业硕士学位。
- Cristina Csimma currently serves as a board director and chair of the Nominating and Corporate Governance Committee of Seneca Biopharma, Inc. previously, Neuralstem Inc. (CUR), having been elected to its board of directors in September 2017. She also serves as the chair of the board of directors of Caraway Therapeutics since April of 2019 (executive chair in 2019), and as a board director of T1D Exchange (non-profit-Type 1 Diabetes), a position she has held since December 2018. She also serves on advisory boards including the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee since 2006; the Harvard and Brigham and Women's Hospital MRCT Center External Advisory Board since 2015 and the TREAT-NMD Advisory Committee for Therapeutics (TACT) since 2009. Dr. Csimma previously served as a Director on the boards of Juniper Pharma (from 2010 until its acquisition by Catalent in 2018), Vtesse Pharma (from 2014 until its acquisition by Sucampo in 2017), was the executive chair and a senior advisor of Exonics Therapeutics (from 2016 to 2017), and was President, founding CEO and board director of Cydan Inc. from 2012 to 2014. She also served on the NIH Blueprint Neurotherapeutics Network External Oversight Committee from 2014 to 2018 the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network from 2013 until 2017 was Vice President of Drug Development at Virdante Pharmaceuticals Inc. from 2009 to 2011 Principal at Clarus Ventures LLC (now Blackstone Life Science) and held roles of increasing responsibility in Clinical Development and Translational Research at Wyeth (now Pfizer), Genetics Institute and Dana Farber Cancer Institute. Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, as well as a Master of Health Professions from Northeastern University.
- Mary Ann Gray
-
Mary Ann Gray, Ph.D.，2010年9月以来，她成为我们的董事会成员。2003年以来。她担任Gray Strategic Advisors, LLC（为生物技术产业提供战略咨询服务）的总裁。从1999年到2003年，她曾是the Federated Kaufmann Fund的高级分析师和投资组合经理。1999年之前，她领导Raymond James & Associates、Warburg Dillon Read和Kidder Peabody的生物技术股票研究部门。她目前在另外两个在Dyax的上市生物制药公司Dyax Corp.和Acadia Pharmaceuticals, Inc.的董事会任职。她也是领导独立董事。她获得佛蒙特大学（the University of Vermont）的药理学博士学位和南卡罗来纳大学 （University of South Carolina）的生物学学士学位。
Mary Ann Gray has served as a member of our board of directors since December 2020. Dr. Gray has been a board member of public biotechnology companies for over 15 years and has held positions of audit committee chair, compensation committee chair and lead independent director. She has served on the board of Rapt Therapeutics since December 2019 Seneca Biopharmaceuticals, Inc. since July 2019 and Sarepta Therapeutics Inc. since December 2018. During her career as a board member she has also served on several other boards including Dyax Corp. from November 2004 until January 2016 Juniper Pharmaceuticals from April 2016 to August 2018 Senomyx from 2010 to December 2018 Galena Biopharma from April 2016 to December 2017 TetraLogic from November 2014 to November 2016 and Acadia Pharmaceuticals from 2005 to June 2016. Dr. Gray has been President of Gray Strategic Advisors, LLC since April 2004 a biotechnology strategic planning and advisory firm. Following an early career as a research scientist, she spent time in scientific positions at biotech and pharmaceutical companies. This was followed by over 7 years as a sell-side research analyst and over 4 years as a portfolio manager at the Federated Kaufmann Fund. Dr. Gray holds a B.S. in biology from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine. - Mary Ann Gray, Ph.D.，2010年9月以来，她成为我们的董事会成员。2003年以来。她担任Gray Strategic Advisors, LLC（为生物技术产业提供战略咨询服务）的总裁。从1999年到2003年，她曾是the Federated Kaufmann Fund的高级分析师和投资组合经理。1999年之前，她领导Raymond James & Associates、Warburg Dillon Read和Kidder Peabody的生物技术股票研究部门。她目前在另外两个在Dyax的上市生物制药公司Dyax Corp.和Acadia Pharmaceuticals, Inc.的董事会任职。她也是领导独立董事。她获得佛蒙特大学（the University of Vermont）的药理学博士学位和南卡罗来纳大学 （University of South Carolina）的生物学学士学位。
- Mary Ann Gray has served as a member of our board of directors since December 2020. Dr. Gray has been a board member of public biotechnology companies for over 15 years and has held positions of audit committee chair, compensation committee chair and lead independent director. She has served on the board of Rapt Therapeutics since December 2019 Seneca Biopharmaceuticals, Inc. since July 2019 and Sarepta Therapeutics Inc. since December 2018. During her career as a board member she has also served on several other boards including Dyax Corp. from November 2004 until January 2016 Juniper Pharmaceuticals from April 2016 to August 2018 Senomyx from 2010 to December 2018 Galena Biopharma from April 2016 to December 2017 TetraLogic from November 2014 to November 2016 and Acadia Pharmaceuticals from 2005 to June 2016. Dr. Gray has been President of Gray Strategic Advisors, LLC since April 2004 a biotechnology strategic planning and advisory firm. Following an early career as a research scientist, she spent time in scientific positions at biotech and pharmaceutical companies. This was followed by over 7 years as a sell-side research analyst and over 4 years as a portfolio manager at the Federated Kaufmann Fund. Dr. Gray holds a B.S. in biology from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.
- Scott V. Ogilvie
-
从2008年2月起，Scott V. Ogilvie,担任Genspera, Inc.董事会董事。目前，Mr. Ogilvie担任AFIN International, Inc.总裁，该公司是一家私募股权/业务咨询公司，是他于2006年创办的。此外，从2011年9月起，Mr. Ogilvie成为私人战略咨询公司Wirthlin Worldwide International和M＆A公司的合伙人。2009年12月31日之前，他担任Gulf Enterprises International, Ltd.的CEO。从2006年8月起，他担任此职位。Mr. Ogilvie之前曾是CIC Group, Inc.的首席运行官，从2001年至2007年，他担任投资经理的职位。他作为Hill, Farrer & Burrill的公司和证券律师开始了其职业生涯。他在融资，房地产，科技公司拥有丰富的上市和私人公司的管理和董事会的经验。Mr. Ogilvie目前任职于Neuralstem, Inc. NYSE AMEX:CUR, Preferred Voice Inc. OTCBB: PRFV 和 Derycz Scientific, Inc. (OTCBB: DYSC).董事会。
Scott V. Ogilvie, served as a director on our board from February 2008 until March 26 2020 the date that he resigned from our board. Mr. Ogilvie is currently the Executive Chairman of Formula Four Beverages, Inc., a functional beverage company that manufactures and sell OXiGEN water. Additionally, Mr. Ogilvie is currently the President of AFIN International, Inc., an international private equity and strategic advisory firm, which he founded in 2006. Prior to December 31 2009 he was CEO of Gulf Enterprises International, Ltd, an investment and strategic advisory company with primary activities in the Middle East and North Africa. He held this position since August 2006. Mr. Ogilvie previously served as Chief Operating Officer of CIC Group, Inc., an investment manager, a position he held from 2001 to 2007. He began his career as a corporate and securities lawyer with Hill, Farrer & Burrill, and has extensive public and private corporate management and board experience in finance, real estate, and life science and technology companies. During the past 5 years, Mr. Ogilvie has served on the board of directors of Inpsyr Therapeutics, Inc. OTCQB: NSPX and Oxigenesis, Inc. and the Advisory Board of Profusa, Inc.. - 从2008年2月起，Scott V. Ogilvie,担任Genspera, Inc.董事会董事。目前，Mr. Ogilvie担任AFIN International, Inc.总裁，该公司是一家私募股权/业务咨询公司，是他于2006年创办的。此外，从2011年9月起，Mr. Ogilvie成为私人战略咨询公司Wirthlin Worldwide International和M＆A公司的合伙人。2009年12月31日之前，他担任Gulf Enterprises International, Ltd.的CEO。从2006年8月起，他担任此职位。Mr. Ogilvie之前曾是CIC Group, Inc.的首席运行官，从2001年至2007年，他担任投资经理的职位。他作为Hill, Farrer & Burrill的公司和证券律师开始了其职业生涯。他在融资，房地产，科技公司拥有丰富的上市和私人公司的管理和董事会的经验。Mr. Ogilvie目前任职于Neuralstem, Inc. NYSE AMEX:CUR, Preferred Voice Inc. OTCBB: PRFV 和 Derycz Scientific, Inc. (OTCBB: DYSC).董事会。
- Scott V. Ogilvie, served as a director on our board from February 2008 until March 26 2020 the date that he resigned from our board. Mr. Ogilvie is currently the Executive Chairman of Formula Four Beverages, Inc., a functional beverage company that manufactures and sell OXiGEN water. Additionally, Mr. Ogilvie is currently the President of AFIN International, Inc., an international private equity and strategic advisory firm, which he founded in 2006. Prior to December 31 2009 he was CEO of Gulf Enterprises International, Ltd, an investment and strategic advisory company with primary activities in the Middle East and North Africa. He held this position since August 2006. Mr. Ogilvie previously served as Chief Operating Officer of CIC Group, Inc., an investment manager, a position he held from 2001 to 2007. He began his career as a corporate and securities lawyer with Hill, Farrer & Burrill, and has extensive public and private corporate management and board experience in finance, real estate, and life science and technology companies. During the past 5 years, Mr. Ogilvie has served on the board of directors of Inpsyr Therapeutics, Inc. OTCQB: NSPX and Oxigenesis, Inc. and the Advisory Board of Profusa, Inc..